Artículos del autor

solaci

Antiplatelet

ESC 2020 | Against the Grain, ASA Monotherapy Appears Superior after TAVR

After TAVR, patients with no anticoagulation indication are favored by monotherapy with aspirin (ASA) vs. dual antiaggregation...
solaci -
Other

ESC 2020 | New SGLT2 Inhibitor Impacts Heart Failure Mortality

Empagliflozin is the second drug from the SGLT2 receptor inhibitor family to show a significant benefit in...
solaci -
Other

ESC 2020 | New Drug Improves Functional Capacity in Hypertrophic Cardiomyopathy

In patients with hypertrophic cardiomyopathy, myosin inhibitor mavacamten plus optimal medical therapy improved hemodynamics, functional capacity, and...
solaci -
Institutional News

The Most Read Articles of August in Interventional Cardiology

01- Myocardial Injury for COVID-19 Even in Young Patients with Mild Symptoms Most young COVID-19 patients not requiring...
solaci -
Other

ESC 2020 | Atrial Fibrillation and Rhythm Control: A Matter of Time?

Early rhythm control therapy in patients recently diagnosed with atrial fibrillation reduces the risk of cardiovascular events...
solaci -
ESC 2020

ESC 2020

Here are the most important articles of the Virtual ESC 2020. If you cannot view the articles, click...
solaci -
Acute coronary syndromes

Can Aspirin Use Be Interrupted After Angioplasty?

Aspirin discontinuation 1 to 3 months after angioplasty with continued P2Y12 inhibitor therapy reduces the bleeding risk without...
solaci -
Structural heart disease

3rd Generation Valves in Large and X-Large Annuli

In patients with large and extra-large annuli, transcatheter aortic valve replacement (TAVR) is safe and feasible with...
solaci -